Additionally, the effects of amcenestrant on ER degradation, through the assessment of tumor biomarker (Ki67, B cell lymphoma 2 [Bcl-2], and PgR) expression, and ESR1 mutation profiles were investigated. This evidence concerns the gene PGR and neoplasm.